Rhone-poulenc Rorer Pharmaceuticals Inc.

Aventis Pharma Deutschland, Gmbh

Aventis Pharmaceuticals Inc.

Michael R Becker

William R Ewing

Yong Mi Choi-Sledeski

Alfred P Spada

Heinz W Pauls

Henry W Pauls

Roderick S Davis

Jeffrey N Barton

Yong Gong

Daniel Michael Green

Daniel G McGarry

Daniel L Cheney

Christopher J Burns

Timothy Francis Gallagher

Wei He

Michael R Myers

Stephen M Condon

Kent W Neuenschwander

Joseph M Karpinski

Bruce F Molino

Scott I Klein

Robert D Groneberg

Robert L Morris

Aiwen Li

Julian Roy Levell

Gregory Bernard Poli

Barbara Hanney

Jean-Francois Sabuco

Mark Czekaj

Jeffrey C Pelletier

Mark A Bobko

John Ziqi Jiang

Jeffrey M Dener

Jonathan S Mason

Wan F Lau

Jonathan Stephen Mason

This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa.

Substituted oxoazaheterocyclyl compounds

The compounds of formula I herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds

The compounds of formula I herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, for treating a patient suffering from, or subject to, a physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds

The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

Substituted sulfonic acid

The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

Substituted (sulfinic acid, sulfonic acid, sulfonylamino or

The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are Factor Xa inhibitors. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.

This invention relates to novel peptide and pseudopeptide derivatives and analogs of aspartic acid which are useful as inhibitors of platelet aggregation and thrombus formation in mammalian blood, to pharmaceutical compositions including such compounds, and to their use in inhibiting thrombus formation and platelet aggregation in mammals.

Antithrombotic peptides and pseudopeptides

Growing community of inventors

Norristown, PA, United States of America

Michael R Becker